Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1192)
Drug Name
Olopatadine
Synonyms
Olopatadin; Olopatadina; Olopatadine; ALO-4943A; D27V6190PM; KW-4679; KW-4943A; OLOPATADINE HYDROCHLORIDE; Olopatadine (INN); Olopatadine [INN:BAN]; Olopatadinum; Patanol; SR-01000763388; (Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid; 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid; 113806-05-6; 140462-76-6; 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid; AC1NQXZH; CHEMBL1719; Pazeo; UNII-D27V6190PM
Indication Conjunctivitis [ICD11: 9A60] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 337.4 Topological Polar Surface Area 49.8
Heavy Atom Count 25 Rotatable Bond Count 5
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 4
Cross-matching ID
PubChem CID
5281071
PubChem SID
9991 ; 8616501 ; 14851325 ; 39289993 ; 46506025 ; 49830421 ; 50064183 ; 50339892 ; 53788070 ; 57357997 ; 85209467 ; 92308886 ; 93166443 ; 96024980 ; 103916408 ; 113854504 ; 117867960 ; 118048374 ; 118313762 ; 124974068 ; 126682737 ; 131839756 ; 134338320 ; 135076611 ; 137005453 ; 137233305 ; 142121621 ; 160964111 ; 163669016 ; 170499432 ; 175266654 ; 175435402 ; 176484058 ; 176484854 ; 177749229 ; 178103823 ; 179149624 ; 179225235 ; 184623003 ; 223655359 ; 224131802 ; 226396615 ; 251916843 ; 251918082 ; 251960673 ; 252391226 ; 252429690 ; 252671957
ChEBI ID
CHEBI:94593
CAS Number
113806-05-6
TTD Drug ID
D05GPO
Formula
C21H23NO3
Canonical SMILES
CN(C)CCC=C1C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
InChI
1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
InChIKey
JBIMVDZLSHOPLA-LSCVHKIXSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
N-desmethyl olopatadine DM002294
14127209
Oxidation - N-Demethylation 1 [3]
Olopatadine metabolite M5 DM002296 N. A. Conjugation - Sulfation 1 [3]
Olopatadine N-oxide metabolite DM002298
9950431
Unclear 1 [4]
Olopatadine metabolite M2 DM002295
14127211
Unclear 2 [3]
Olopatadine metabolite M4 DM002297 N. A. Unclear 2 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR001821 Olopatadine N-desmethyl olopatadine Oxidation - N-Demethylation CYP3A4 [3]
MR001822 Olopatadine Olopatadine metabolite M5 Conjugation - Sulfation Unclear [3]
MR001823 Olopatadine Olopatadine N-oxide metabolite Unclear FMO1 ... [4]
MR001819 N-desmethyl olopatadine Olopatadine metabolite M2 Unclear Unclear [3]
MR001820 Olopatadine metabolite M5 Olopatadine metabolite M4 Unclear Unclear [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 2B6 (CYP2B6) DME0020 Homo sapiens
CP2B6_HUMAN
1.14.14.1
[2]
Cytochrome P450 2E1 (CYP2E1) DME0013 Homo sapiens
CP2E1_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Dimethylaniline oxidase 1 (FMO1) DME0059 Homo sapiens
FMO1_HUMAN
1.14.13.8
[2]
Dimethylaniline oxidase 2 (FMO2) DME0283 Homo sapiens
FMO2_HUMAN
1.14.13.8
[2]
⏷ Show the Full List of 6  DME(s)
References
1 Olopatadine was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities Drug Metab Dispos. 2002 Dec;30(12):1504-11. doi: 10.1124/dmd.30.12.1504.
3 Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos. 2002 Dec;30(12):1504-11.
4 U. S. FDA Label -Olopatadine

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.